Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1501MR)

This product GTTS-WQ1501MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1501MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ71MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5315MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ13532MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ3808MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ3736MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ6074MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ14842MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ13325MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06741086
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW